Nimotuzumab combined with cisplatin and 5-FU in treatment of patients with advanced esophageal squamous cell carcinoma

Journal of Practical Oncology

Volumn 28, Issue 6, 2013, Pages 650-653

  Xu, Zhen ^a   Chen, Jia ^b   Tao, Min ^c  

^a China   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Antibodies; Cisplatin therapeutic use; Combination; Drug therapy; Esophageal neoplasms drug therapy; Fluorouracil therapeutic use; Monoclonal

Indexed keywords

CISPLATIN; FLUOROURACIL; NIMOTUZUMAB;

ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84892188334     PISSN: 10011692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Therasse P, Arbuck SG, Eisenhauer E.A., et al New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
2. U. S. Department of Health and Human Services. Appendix B-modified from common terminology criteria for adverse events (CTCAE) (version 3. 0) [J]. Clin Cynecoloncol, 2007, 23:735-763.
3. Vashi PG, Gupta D, Tan B. Colon carcinoma with unusual metastasis to the esophagus manifesting as multiple nodules and dysphagia: Management with systemic chemotherapy [J]. Case Rep Gastroenterol, 2012, 6(2): 484.
4. Ilson DH. Esophageal cancer chemotherapy: recent advances [J]. Gastrointest Cancer Res, 2008, 2(2): 85-92.
5. Boone J, van Hillegersberg R, Offerhaus GJ, et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis [J]. Dis Esophagus, 2009, 22(6): 496-504.
6. Egamberdiev DM, Djuraev MD. Tuydjanova K, et al. Our experience in the use of Trastuzumab in patients with advanced stomach cancer [J]. Ann Oncol, 2010, 21 (8): 839.
7. Kelsen D, Jhawer M, Ilson D., et al Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gas Uroesophageal (GE) adenocarcinoma; results of a phase II clinical trial[J]. Clin Oncol, 2009, 27 (15S): 4512.